EUCTR2007-003872-20-HU进行中（未招募）不适用
A RANDOMISED, DOUBLE-BLIND, SINGLE-DOSE, TWO-WAY CROSSOVER STUDY TO ASSESS THE BRONCHODILATING PROPERTIES OF A NEW GENERIC DRY POWDER FORMOTEROL FORMULATION GIVEN FROM A NOVEL DRY POWDER INHALER COMPARED TO THE REFERENCE FORADIL® AEROLIZER® IN MODERATE TO SEVERE ADULT ASTHMATIC SUBJECTS
aboratorios Liconsa S.A.0 个研究点目标入组 72 人开始时间: 2007年8月23日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 72
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •At study entry:
- •1.Subjects who are willing to give written informed consent to participate in the study.
- •2.Male and female asthmatic subjects, legally aged 18 - 75 years, inclusive.
- •3.Documented asthma for at least 6 months before screening as per the current GINA guidelines, treated with or without the use of inhaled corticosteroids. Patients on inhaled corticosteroids must have followed a stable treatment regimen for at least the previous 4 weeks prior to the Screening Visit
- •4.Subjects with a baseline FEV1 40% - 70% of the predicted normal value for age, height and gender after withholding short acting beta2-agonists/anticholinergics for at least 8 hours and methylxanthines, long acting ?2-agonists/ anticholinergics for at least 32 hours. Qualifying lung function parameters will be measured using standardized equipment for all participating centres. Appropriate standard formulae from the European Community for Coal and Steel (Quanjer et al., 1993) will be used for the calculation of the predicted FEV1 values. The reference (ECCS) values will be generated by the specific spirometer provided by the Sponsor to the investigator.
- •5.Subjects who demonstrate a reversibility in airway obstruction (increase in FEV1 of ? 15% and an increase of at least 250 ml over pre-salbutamol values) 30 minutes after the inhalation of a dose of 200?g salbutamol from a standard pMDI.
- •6.Subjects who are able to handle dry powder inhalers correctly.
- •7.Subjects who are able to perform lung function tests properly.
- •On study days:
- •1.A pre-dose baseline FEV1 within ±10% of the value obtained at the Screening Visit.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects will be excluded from participation if any of the following apply:
- •1.Subjects currently receiving oral, intravenous or intramuscular corticosteroid therapy or who have received such corticosteroid therapy in the 3 months preceding the screening or who have received more than 3 short courses of such therapy in the last year.
- •2.Subjects currently receiving therapy for an upper respiratory tract infection or who have received such a therapy in the month prior to the start of the study. Subjects who require such a treatment during the run-in or washout periods will be discontinued from the trial.
- •3.Subjects who have been hospitalized or have received emergency treatment for an exacerbation of asthma in the 3 months prior to the start of the study. Subjects who require such a treatment during the run-in or washout periods will be discontinued from the trial.
- •4.Subjects with a known or suspected hypersensitivity to formoterol or other ß2-receptor agonists or any other ingredients of the study medications.
- •5.Subject who show signs of paradoxical bronchospasm after salbutamol inhalation (defined as having the lowest FEV1 within 30 minutes after inhalation smaller or equal to the lowest pre-dose baseline FEV1).
- •6.Subjects with any of the following concurrent conditions:
- •Uncontrolled diabetes mellitus defined as fasting plasma glucose ?10 mmol/L
- •Evidence of current neoplastic disease other than basal cell carcinoma
- •Evidence or history of tuberculosis
- •Evidence or history of significant cardiovascular disease
- •Respiratory disorders other than asthma or allergic rhinitis
- •Clinically significant hepatic or renal disease
- •Evidence or history of alcohol or drug abuse
- •Evidence or history of low potassium levels (i.e., potassium values below the lower limit of normal, as per the central laboratory results at the Screening Visit) or concomitant use of non-potassium sparing diuretics.
- •7.Subjects currently receiving or who intend to receive during the study any of the following medications, except what is specifically permitted during the run-in and/or washout periods:
- •Mono-amine-oxidase inhibitors or tricyclic anti-depressants
- •Leukotriene-antagonists, either currently or during the last week preceding the screening visit
- •Non-selective beta-receptor blocking agents
- •Use of anticholinergics, other inhaled ?2-agonists or methylxanthines:
- •These medications are permitted during the run-in and washout periods, provided that a washout period of at least 8 hours prior to screening and both treatment days is adhered to for short acting anticholinergics/short acting ?2-agonists and a washout period of 32 hours prior to screening and both treatment days is adhered to for methylxanthines/long acting beta2-agonists/ long acting anticholinergics.
- •Oral beta2-agonists. A washout period of 72 hours is required prior to the screening visit.
- •Use of any other medications that contain products known to have ß2-agonistic activity (i.e. ephedrine):
- •A washout period of 72 hours prior to screening is required.
- •8.Heavy smokers defined as smoking at least 10 cigarettes per day or ex-smokers who smoked more than 10 pack years.
- •Pack-years are calculated by dividing the number of cigarettes smoked per day by 20 (the number of cigarettes in a pack) and multiplying this figure by the number of years a person has smoked. For example, a person who smokes 40 cigarettes a day and has smoked for 10 years would have a 20 pack-year smoking history
研究者
相似试验
已完成
1 期
Comparison between two injectable formulations of anti- cancer drug Pertuzumab by studying their blood levels and safety in healthy adult male subjectsCTRI/2023/06/054259CinnaGen Research and Production Company80
已完成
不适用
A RANDOMIZED, SINGLE DOSE, DOUBLE BLIND, PARALLEL GROUP, PHARMACOKINETIC TRIAL, COMPARING ONS-1045 (ONCOBIOLOGICS INC, USA) TO 2 ARMS OF AVASTIN® (GENENTECH, SOUTH SAN FRANCISCO, USA; ROCHE, SWITZERLAND) IN HEALTHY MALE VOLUNTEERS10027656CancerNL-OMON41859Oncobiologics Inc135
已完成
不适用
A DOUBLE-BLINDED, PLACEBO-CONTROLLED, SINGLE DOSE AND MULTIPLE-DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND PROOF OF CONCEPT OF DM-199 IN HEALTHY SUBJECTS AND PATIENTS WITH TYPE 2 DIABETES MELLITUSType2 Diabetes Mellitus: bloodglucose.10018424NL-OMON40545DiaMedica Inc.96
进行中（未招募）
不适用
A study on the safety, tolerability and the effect of DM-199 on the body, a new agent for the treatment of Diabetes Mellitus Type 2, after single- and multiple dosing in healthy volunteers and Diabetes Mellitus Type 2 patients.Diabetes Mellitus type 2MedDRA version: 16.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2013-000225-30-NLDiaMedica USA Inc.
已完成
1 期
A phase I biosimilar study to compare the pharmacokinetics, Pharmacodynamics, safety and tolerability of BP14 (Pegfilgrastim) with EU-approved Neulasta® in healthy male adult volunteers following a subcutaneous (SC- under the skin) injection.Chemotherapy-induced-neutropeniaCancer - Any cancerBlood - Haematological diseasesACTRN12620000657921CURATEQ BIOLOGICS PRIVATE LIMITED124